Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Claseprubart · DNTH103

Monoclonal antibody · developed by Dianthus Therapeutics

Phase 3 Most advanced trial
DNTH Developer
1 Registered trials

What is Claseprubart?

Claseprubart (DNTH103) is a drug studied in chronic inflammatory demyelinating polyneuropathy, a chronic immune-mediated disorder of the peripheral nerves.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DNTH103
Drug type
Monoclonal antibody
Therapy area
Neurology
Developer
Dianthus Therapeutics (DNTH)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
LDW8BPL8GB

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06858579 Phase 3 Chronic Inflammatory Demyelinating Polyneuropathy Recruiting DNTH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Inflammatory Demyelinating Polyneuropathy

Follow DNTH, the company behind Claseprubart

See DNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DNTH catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.